Cargando…

Postoperative Ketoacidosis With Hypoglycemia in a Nondiabetic Patient Taking Dapagliflozin for Heart Failure: A Case Report

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are relatively new antidiabetic drugs, which have been recently approved for heart failure treatment. Although treatment interruption is recommended 3 to 4 days before surgery, it is unclear whether SGLT-2 inhibitors should be discontinued when pres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seki, Hiroyuki, Watanabe, Hidenobu, Yorozu, Tomoko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323548/ https://www.ncbi.nlm.nih.gov/pubmed/35285818 http://dx.doi.org/10.1213/XAA.0000000000001570

Ejemplares similares

Multicentre prospective observational study of sodium-glucose cotransporter-2 inhibitor-associated postoperative ketoacidosis: the SAPKA study protocol
por: Seki, Hiroyuki, et al.
Publicado: (2021)

Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report
por: Yeo, Sang Mok, et al.
Publicado: (2019)

Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report
por: Chou, Yu-Mou, et al.
Publicado: (2018)

Sudden-onset Hypoglycemia Following Fluid Replacement in a Patient with Dapagliflozin-induced Diabetic Ketoacidosis Without Prior Insulin Use: Case Report
por: Elshimy, Ghada, et al.
Publicado: (2019)

SUN-184 Sertraline-Induced Hypoglycemia in Nondiabetic Patients
por: Bhargava, Pooja, et al.
Publicado: (2019)

Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis
por: Iqbal, Iqra, et al.
Publicado: (2019)

A review on nondiabetic hypoglycemia from various causes: Case series report
por: Gan, Lulu, et al.
Publicado: (2023)

Critical Illness Associated Fatal Hypoglycemia in a Nondiabetic Male
por: Toor, Amit, et al.
Publicado: (2019)

Simple Reason for Hypoglycemia: ACE Inhibitor-induced Severe Recurrent Hypoglycemia in a Nondiabetic Patient
por: Elshimy, Ghada, et al.
Publicado: (2019)

Another “D” in MUDPILES? A Review of Diet-Associated Nondiabetic Ketoacidosis
por: Ullah, Waqas, et al.
Publicado: (2018)

Diabetic ketoacidosis inducing myocardial infarction secondary to treatment with dapagliflozin: a case report
por: Gil‐Perdomo, José M., et al.
Publicado: (2017)

Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin
por: Pujara, Shreya, et al.
Publicado: (2017)

Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy
por: Papadokostaki, Eleni, et al.
Publicado: (2019)

Current Status of Dapagliflozin in Congestive Heart Failure
por: Palandurkar, Gopal, et al.
Publicado: (2022)

Residual paralysis caused by 50 mg rocuronium after reversal with 4 mg/kg sugammadex: a case report
por: Uzawa, Kohji, et al.
Publicado: (2021)

Normoglycemic diabetic ketoacidosis in a type 2 diabetes patient on dapagliflozin: A case report
por: Matli, Venkata Vinod Kumar, et al.
Publicado: (2021)

Starvation Ketoacidosis With Hypoglycemia in a Patient With Chronic Pancreatitis
por: Kakurai, Masakazu, et al.
Publicado: (2021)

A Case of Severe Lactation Ketoacidosis in a Nondiabetic Mother on a Ketogenic Diet
por: Borhan, Marisa Khatijah, et al.
Publicado: (2023)

Management of Hypoglycemia in Nondiabetic Palliative Care Patients: A Prognosis-Based Approach
por: Kok, Victor C., et al.
Publicado: (2016)

Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis
por: Badwal, Karun, et al.
Publicado: (2018)

The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study
por: di Mauro, Gabriella, et al.
Publicado: (2022)

Diabetic Ketoacidosis on Hospitalization with COVID-19 in a Previously Nondiabetic Patient: A Review of Pathophysiology
por: Eskandarani, Rawan M, et al.
Publicado: (2020)

Acute Pancreatitis as an Unusual Culprit of Diabetic Ketoacidosis in a Nondiabetic: A Case-Based Review
por: Imburgio, Steven, et al.
Publicado: (2023)

Resolution of Hypoglycemia Following Cessation of Sacubitril–Valsartan Combination Therapy in a Nondiabetic Patient
por: Morgan, Georgia, et al.
Publicado: (2022)

PICC insertion in the sitting position for a patient with congestive heart failure: A case report
por: Mitsuda, Shingo, et al.
Publicado: (2019)

Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report
por: Lee, In Hee, et al.
Publicado: (2020)

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
por: Gupta, Manasvi, et al.
Publicado: (2021)

Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Bleeding After Central Venous Catheter Placement in a Patient With Undiagnosed Acquired Hemophilia A: A Case Report
por: Noguchi, Hikari, et al.
Publicado: (2022)

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
por: Blair, Hannah A.
Publicado: (2021)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
por: Håkansson, Erik, et al.
Publicado: (2021)

Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports
por: Seki, Hiroyuki, et al.
Publicado: (2023)

Symptomatic hypoglycemia in a nondiabetic adult female recovering from mild COVID‐19 infection: A case report
por: Grover, Jayant, et al.
Publicado: (2022)

Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Who Underwent Surgery for Pancreatic Carcinoma: A Case Report
por: Luo, Xiaoqian, et al.
Publicado: (2022)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020)

Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
por: Williams, David M., et al.
Publicado: (2020)

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
por: Isaza, Nicolas, et al.
Publicado: (2021)

Dapagliflozin for heart failure according to body mass index: the DELIVER trial( )
por: Adamson, Carly, et al.
Publicado: (2022)

Effect of Dapagliflozin on Exercise Capacity and Cardiovascular Risk in Patients with Heart Failure
por: Nazer, Rakan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_atbkt54cerrt3jfim8jmgdi8bp